1. Home
  2. WLK vs PRAX Comparison

WLK vs PRAX Comparison

Compare WLK & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westlake Corporation

WLK

Westlake Corporation

HOLD

Current Price

$68.80

Market Cap

9.0B

Sector

Industrials

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$300.65

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLK
PRAX
Founded
1986
2015
Country
United States
United States
Employees
N/A
10998
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
8.3B
IPO Year
2004
2020

Fundamental Metrics

Financial Performance
Metric
WLK
PRAX
Price
$68.80
$300.65
Analyst Decision
Buy
Strong Buy
Analyst Count
15
15
Target Price
$106.87
$572.13
AVG Volume (30 Days)
593.4K
306.3K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
1.90%
N/A
EPS Growth
N/A
N/A
EPS
0.70
N/A
Revenue
$11,170,000,000.00
N/A
Revenue This Year
$5.51
N/A
Revenue Next Year
$3.74
$7,758.26
P/E Ratio
$96.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$56.33
$46.99
52 Week High
$124.23
$392.70

Technical Indicators

Market Signals
Indicator
WLK
PRAX
Relative Strength Index (RSI) 33.09 32.68
Support Level N/A $290.53
Resistance Level $77.46 $328.24
Average True Range (ATR) 2.13 13.88
MACD -0.44 -6.01
Stochastic Oscillator 4.48 9.99

Price Performance

Historical Comparison
WLK
PRAX

About WLK Westlake Corporation

Westlake is a forward-integrated commodity chemicals firm based in Houston. It began as a single low-density polyethylene plant and expanded its capabilities to include ethylene, vinyl chloride monomers, and polyvinyl chloride over the next two decades. The acquisition of Axiall in 2016 made it a North American leader in chlor-alkali and PVC. Today, Westlake has two defined segments: performance and essential materials, and housing and infrastructure products. The HIP segment began operating in 2022 following a series of acquisitions in the building products space. The firm aims to maximize the value of its chemical production by integrating with the HIP segment, realizing the higher margins of finished commercial goods.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: